Antiangiogenic properties of low molecular weight heparin – does tissue factor provide the answer?

• References

• 1 Kramer KL, Yost HJ. Heparan sulfate core proteins in cell-cell signaling. Annu Rev Genet 2003; 37: 461-84.
• 2 van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci 2001; 936: 426-37.
• 3 Folkman J, Langer R, Linhardt RJ. et al. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983; 221: 719-25.
• 4 Bashkin P, Doctrow S, Klagsbrun M. et al. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989; 28: 1737-43.
• 5 Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992; 313: 355-64.
• 6 Collen A, Smorenburg SM, Peters E. et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro . Cancer Res 2000; 60: 6196-200.
• 7 Presta M, Leali D, Stabile H. et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003; 09: 553-66.
• 8 Lupu C, Poulsen E, Roquefeuil S. et al. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
• 9 Westmuckett AD, Kakkar VV, Hamuro T. et al. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro. Thromb Haemost 2001; 86: 1547-54.
• 10 Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000; 30: 48-56.
• 11 Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol 2003; 43: 727-34.
• 12 Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, Tinzaparin, is mediated by Tissue Factor Pathyway Inhibitor. Thromb Haemost 2004; 92: 627-33.
• 13 Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23: 2110-5.
• 14 Chen J, Bierhaus A, Schiekofer S. et al. Tissue factor—a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001; 86: 334-45.
• 15 Versteeg HH, Peppelenbosch MP, Spek CA. Tissue factor signal transduction in angiogenesis. Carcinogenesis 2003; 24: 1009-13.
• 16 Carmeliet P, Mackman N, Moons L. et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-5.
• 17 Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-22.
• 18 Riewald M, Ruf W. Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med 2002; 12: 149-54.
• 19 Sato Y, Asada Y, Marutsuka K. et al. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996; 75: 389-92.
• 20 Zhang Y, Deng Y, Luther T. et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-7.
• 21 Abe K, Shoji M, Chen J. et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A 1999; 96: 8663-8.
• 22 Bromberg ME, Sundaram R, Homer RJ. et al. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999; 82: 88-92.
• 23 Belting M, Dorrell MI, Sandgren S. et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004; 10: 502-9.
• 24 Kopp CW, Holzenbein T, Steiner S. et al. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity. Blood 2004; 103: 1653-61.